120 related articles for article (PubMed ID: 9584952)
1. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target.
Wikstrand CJ; Reist CJ; Archer GE; Zalutsky MR; Bigner DD
J Neurovirol; 1998 Apr; 4(2):148-58. PubMed ID: 9584952
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.
Wikstrand CJ; Hale LP; Batra SK; Hill ML; Humphrey PA; Kurpad SN; McLendon RE; Moscatello D; Pegram CN; Reist CJ
Cancer Res; 1995 Jul; 55(14):3140-8. PubMed ID: 7606735
[TBL] [Abstract][Full Text] [Related]
3. Tumor antigens in astrocytic gliomas.
Kurpad SN; Zhao XG; Wikstrand CJ; Batra SK; McLendon RE; Bigner DD
Glia; 1995 Nov; 15(3):244-56. PubMed ID: 8586461
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of human glioma xenografts with unlabeled, 131I-, or 125I-labeled monoclonal antibody 425 to epidermal growth factor receptor.
Bender H; Takahashi H; Adachi K; Belser P; Liang SH; Prewett M; Schrappe M; Sutter A; Rodeck U; Herlyn D
Cancer Res; 1992 Jan; 52(1):121-6. PubMed ID: 1727372
[TBL] [Abstract][Full Text] [Related]
5. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody.
Foulon CF; Reist CJ; Bigner DD; Zalutsky MR
Cancer Res; 2000 Aug; 60(16):4453-60. PubMed ID: 10969792
[TBL] [Abstract][Full Text] [Related]
6. 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.
Kuan CT; Reist CJ; Foulon CF; Lorimer IA; Archer G; Pegram CN; Pastan I; Zalutsky MR; Bigner DD
Clin Cancer Res; 1999 Jun; 5(6):1539-49. PubMed ID: 10389943
[TBL] [Abstract][Full Text] [Related]
7. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts.
Reist CJ; Archer GE; Kurpad SN; Wikstrand CJ; Vaidyanathan G; Willingham MC; Moscatello DK; Wong AJ; Bigner DD; Zalutsky MR
Cancer Res; 1995 Oct; 55(19):4375-82. PubMed ID: 7671250
[TBL] [Abstract][Full Text] [Related]
8. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII.
Wikstrand CJ; McLendon RE; Friedman AH; Bigner DD
Cancer Res; 1997 Sep; 57(18):4130-40. PubMed ID: 9307304
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity.
Lammering G; Hewit TH; Holmes M; Valerie K; Hawkins W; Lin PS; Mikkelsen RB; Schmidt-Ullrich RK
Clin Cancer Res; 2004 Oct; 10(19):6732-43. PubMed ID: 15475464
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW
Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643
[TBL] [Abstract][Full Text] [Related]
11. Targeting epidermal growth factor receptor variant III: a novel strategy for the therapy of malignant glioma.
Sonabend AM; Dana K; Lesniak MS
Expert Rev Anticancer Ther; 2007 Dec; 7(12 Suppl):S45-50. PubMed ID: 18076318
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization.
Johns TG; Perera RM; Vernes SC; Vitali AA; Cao DX; Cavenee WK; Scott AM; Furnari FB
Clin Cancer Res; 2007 Mar; 13(6):1911-25. PubMed ID: 17363548
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
Tang CK; Gong XQ; Moscatello DK; Wong AJ; Lippman ME
Cancer Res; 2000 Jun; 60(11):3081-7. PubMed ID: 10850460
[TBL] [Abstract][Full Text] [Related]
14. Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance.
Shankar S; Vaidyanathan G; Kuan CT; Bigner DD; Zalutsky MR
Nucl Med Biol; 2006 Jan; 33(1):101-10. PubMed ID: 16459265
[TBL] [Abstract][Full Text] [Related]
15. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
[TBL] [Abstract][Full Text] [Related]
16. Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors.
Lorimer IA; Wikstrand CJ; Batra SK; Bigner DD; Pastan I
Clin Cancer Res; 1995 Aug; 1(8):859-64. PubMed ID: 9816055
[TBL] [Abstract][Full Text] [Related]
17. Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate.
Reist CJ; Archer GE; Wikstrand CJ; Bigner DD; Zalutsky MR
Cancer Res; 1997 Apr; 57(8):1510-5. PubMed ID: 9108453
[TBL] [Abstract][Full Text] [Related]
18. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
Luwor RB; Johns TG; Murone C; Huang HJ; Cavenee WK; Ritter G; Old LJ; Burgess AW; Scott AM
Cancer Res; 2001 Jul; 61(14):5355-61. PubMed ID: 11454674
[TBL] [Abstract][Full Text] [Related]
20. EGF receptor variant III as a target antigen for tumor immunotherapy.
Li G; Wong AJ
Expert Rev Vaccines; 2008 Sep; 7(7):977-85. PubMed ID: 18767947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
